MX2022001717A - Aplicacion de polipeptido o derivado del mismo. - Google Patents

Aplicacion de polipeptido o derivado del mismo.

Info

Publication number
MX2022001717A
MX2022001717A MX2022001717A MX2022001717A MX2022001717A MX 2022001717 A MX2022001717 A MX 2022001717A MX 2022001717 A MX2022001717 A MX 2022001717A MX 2022001717 A MX2022001717 A MX 2022001717A MX 2022001717 A MX2022001717 A MX 2022001717A
Authority
MX
Mexico
Prior art keywords
acid sequence
amino acid
polypeptide
drugs
tumor
Prior art date
Application number
MX2022001717A
Other languages
English (en)
Inventor
Yi Ding
De Wei
Xiaomei Li
Ling Xiao
Original Assignee
Chengdu Huitai Biomedicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Huitai Biomedicine Co Ltd filed Critical Chengdu Huitai Biomedicine Co Ltd
Publication of MX2022001717A publication Critical patent/MX2022001717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una aplicación de un polipéptido o un derivado del mismo. Específicamente se proporcionan fármacos polipeptídicos antitumorales (secuencia de aminoácidos representada por la SEQ ID NO. 1, y secuencia de aminoácidos obtenida por deleción, sustitución, adición y/o modificación de uno o más aminoácidos de la secuencia de aminoácidos representada por la SEQ ID NO. 1). Estos fármacos tienen ventajas significativas en términos de especificidad de diana farmacológica, actividad biológica de los fármacos, toxicidad de fármacos, coste del tratamiento, y similares. Los polipéptidos o derivados de los mismos capaces de inhibir la actividad de las células tumorales y la metástasis tumoral se diseñan basándose en citocinas implicadas en la formación del microambiente tumoral y el mantenimiento de la homeostasis, y los polipéptidos o derivados de los mismos se aplican además a la preparación de fármacos antitumorales.
MX2022001717A 2019-08-13 2020-08-07 Aplicacion de polipeptido o derivado del mismo. MX2022001717A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910743680.9A CN112386678B (zh) 2019-08-13 2019-08-13 多肽或其衍生物的应用
PCT/CN2020/107686 WO2021027704A1 (zh) 2019-08-13 2020-08-07 多肽或其衍生物的应用

Publications (1)

Publication Number Publication Date
MX2022001717A true MX2022001717A (es) 2022-03-11

Family

ID=74569249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001717A MX2022001717A (es) 2019-08-13 2020-08-07 Aplicacion de polipeptido o derivado del mismo.

Country Status (10)

Country Link
US (1) US20220280594A1 (es)
EP (1) EP4014986A4 (es)
JP (1) JP2022544481A (es)
KR (1) KR20220044291A (es)
CN (1) CN112386678B (es)
AU (1) AU2020327457A1 (es)
CA (1) CA3146530A1 (es)
IL (1) IL290137A (es)
MX (1) MX2022001717A (es)
WO (1) WO2021027704A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246703A1 (zh) * 2022-06-23 2023-12-28 成都倍特新启生物医药有限责任公司 肽抑制剂及其用途
CN114957399B (zh) * 2022-06-29 2023-05-09 湖北工业大学 一种多肽、多肽衍生物及其在制备抗肿瘤药物中的应用
WO2024051616A1 (zh) * 2022-09-09 2024-03-14 湖南大学 一种多肽及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043455A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Therapeutic uses of angiogenin 108-122 and gluten exorphin a5
WO2009043525A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
CN104873986A (zh) * 2015-03-23 2015-09-02 广东药学院 一种治疗肝脏纤维化的siRNA及其应用
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
JP6965362B2 (ja) * 2017-03-01 2021-11-10 チェンドゥ フイタイ バイオメディスン カンパニー リミテッドChengdu Huitai Biomedicine Co., Ltd. ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用
CN109384830B (zh) * 2017-08-09 2021-12-03 成都惠泰生物医药有限公司 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CN110013544B (zh) * 2019-04-23 2021-04-30 中国人民解放军第二军医大学 小分子组合在制备治疗慢性肝损伤的药物中的应用

Also Published As

Publication number Publication date
CA3146530A1 (en) 2021-02-18
JP2022544481A (ja) 2022-10-19
KR20220044291A (ko) 2022-04-07
AU2020327457A1 (en) 2022-03-03
IL290137A (en) 2022-03-01
CN112386678A (zh) 2021-02-23
US20220280594A1 (en) 2022-09-08
WO2021027704A1 (zh) 2021-02-18
EP4014986A1 (en) 2022-06-22
CN112386678B (zh) 2023-07-07
EP4014986A4 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2022001717A (es) Aplicacion de polipeptido o derivado del mismo.
Camilio et al. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
JP5911481B2 (ja) 抗癌性融合タンパク質
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
WO2003104399A3 (en) CANCER-RELATED GENE AS A TARGET IN CHEMOTHERAPY
PH12014501642B1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
KR20160089523A (ko) 전립선 암 치료용 조성물
AU2019330367A1 (en) Recombinant lectin variants
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
WO2018116165A3 (en) Therapeutically active complexes
Hosseini et al. Effect of RGD coupled MDA-7/IL-24 on apoptosis induction in a hepatocellular carcinoma cell line
Giacometti et al. In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci
Ducker et al. USP17-mediated de-ubiquitination and cancer: clients cluster around the cell cycle
PH12020500087A1 (en) Immunogenic compositions comprising cea muc1 and tert
Jaber et al. Synthesis, antiproliferative and antimicrobial activities of (KLAKLAK) 2-NH2 analogue containing nor-Leu and its conjugates with a second pharmacophore
Liu et al. Solubility-enhanced gMYL6 fused with a hexa-lysine tag promotes the cytotoxicity of human NK cells
Ma et al. SDF-1/54-DCN: a novel recombinant chimera with dual inhibitory effects on proliferation and chemotaxis of tumor cells
JP2019506167A5 (es)
RU2018107330A (ru) Индуктор иммунитета
WO2007101222A3 (en) Cancer treatment
WO2003104401A3 (en) TARGETED CANCER GENE IN CHEMOTHERAPY
WO2003104438A3 (en) CANCER-RELATED GENES AS CHEMOTHERAPY TARGETS
KR20230055678A (ko) 암세포 투과성 단백질 전달용 조성물 및 그 용도
MX2019014546A (es) Péptido con actividad anti-cáncer.